| Literature DB >> 36233222 |
Abstract
CRISPR technology affords a simple and robust way to edit the genomes of cells, providing powerful tools for basic research and medicine. While using Cas9 to target a genomic site is very efficient, making a specific mutation at that site is much less so, as it depends on the endogenous DNA repair machinery. Various strategies have been developed to increase the efficiency of knock-in mutagenesis, but often the desired cells remain a small percentage of the total population. To improve efficiency, strategies to select edited cells have been developed. In some applications, a selectable foreign gene is linked directly to the gene of interest (GOI). Alternatively, co-editing, where the GOI is edited along with a selectable gene, enriches the desired cells since the cells that successfully edited the selectable gene are likely to have also edited the GOI. To minimize perturbations of the host genome, "scarless" selection strategies have been developed, where the modified cells are mutated solely in the GOI. In this review, we will discuss strategies employed to improve specific genome editing in mammalian cells, focusing on ways to select successfully edited cells.Entities:
Keywords: CRISPR; HDR-dependent editing; co-editing; genome editing; scarless selection
Mesh:
Year: 2022 PMID: 36233222 PMCID: PMC9569436 DOI: 10.3390/ijms231911919
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Increasing HDR-dependent repair improves yield of CRISPR knock-in cells. Knock-in HDR-dependent mutagenesis at a gene of interest (GOI). At the top, the basal conditions are shown, where few of the cells are HDR-competent. A fraction of these can be edited at the GOI following transfection with Cas9/gRNA and donor DNA. Isolating the desired knock-in edited cells from the total population can be challenging. In the center, cells are treated either genetically or pharmacologically to alter the HDR/NHEJ ratio. As a result, a higher yield of knock-in edited cells is achieved. The bottom row illustrates some methods used to improve HDR-dependent CRISPR editing. The increases in precisely edited cells depend on the method, the target cells and GOI. Created with BioRender.com.
Figure 2Selection marker linked to gene of interest. The selectable gene is linked directly, or through a 2A peptide, to the gene of interest. Note that the donor construct elements are not to scale. A CMV promoter is depicted as an example of an exogenous promoter. HA-L, HA-R; left and right homology arms, respectively. FP; fluorescent protein. CMV; CMV promoter. Created with BioRender.com.
Figure 3Selection marker co-edited with gene of interest. The selectable gene is edited into a locus independent of the gene of interest. Note that the donor construct elements are not to scale and depict a general approach. In this example, a CMV promoter is used to drive expression of the selectable gene. HA-L, HA-R; left and right homology arms, respectively. Created with BioRender.com.
Figure 4Two-step scarless editing with removal of the selectable gene. This figure is based on strategies presented in references [56,60,62,63,64,65,67], although the precise constructs are not fully reproduced, and the depictions are not to scale. The cassettes encode positive and negative selectable genes, depicted here in a general scheme driven by a CMV promoter. The selectable cassettes are contained within the donor DNA for editing the GOI or are included in a donor DNA for co-editing a locus independent of the GOI. HA-L, HA-R; left and right homology arms, respectively. ITR; inverted terminal repeats for later removal of cassette via piggyBac transposase. PBase-ERT2; PBase fused to modified ERT2 for later induction by tamoxifen (4OHT). Created with BioRender.com.
Figure 5Co-editing an endogenous or plasmid-encoded selectable gene. Cells are transfected with Cas9/donor for the GOI, in addition to Cas9/donor for an endogenous gene, or with the HDR-USR reporter plasmid. The co-edited genes provide resistance to selection, and as the genomic perturbations are minimal, these methods are scarless or semi-scarless. Created with BioRender.com.
Selection strategies for CRISPR-edited cells.
| Selection Strategy | Description | Scarless? | Reference |
|---|---|---|---|
| Marker linked to GOI | eFlut plasmid sets for generating dsDNA donors with selectable genes by PCR- for tagging N- or C-termini of endogenous genes | No | [ |
| Foreign selection cassettes are combined in a donor DNA for modifying a GOI | No | [ | |
| Two donor DNAs with different fluorescent protein-expressing selection cassettes for selection of biallelically edited cells | No | [ | |
| GEIS (Gene Editing through an Intronic Selection marker) | Yes, if cassette does not interfere with splicing or GOI expression | [ | |
| Co-editing with independent locus | Co-editing of GOI alongside selectable gene requiring HDR | No | [ |
| COIN (co-incidental insertion) | No | [ | |
| Scarless selection | Gene edit is itself selectable: FACS sorting for TCR in primary human T cells | Yes | [ |
| Two-step scarless selection: insert, then remove selectable marker | Two CRISPR editing steps—first step CRISPR to introduce selectable marker and edit GOI, second CRISPR to remove selectable marker | Yes | [ |
| Selectable cassette flanking mutation in GOI; removal using piggyBac transposase | Co-editing of selectable cassette followed by removal by transfected piggyBac transposase | Yes, if cassette not re-inserted by transposase | [ |
| Co-editing with removable selection cassette expressing PBase-ERT2 for induction of cassette removal with 4OHT | Yes, if cassette not re-inserted by transposase | [ | |
| Editing of GOI with donor containing removable selection cassette. Removal via transfection with excision-only PBase | Yes | [ | |
| Two excisable fluorescent donor cassettes to permit sorting of biallelic clones, removal of cassettes with excision-only PBase | Yes | [ | |
| Co-editing with selectable endogenous gene | Co-editing of sodium/potassium pump for resistance to ouabain | Semi | [ |
| Co-editing of HBEGF for resistance to diphtheria toxin, “Xential” | Semi | [ | |
| Co-editing of TAF1ts, selective gene restored to wt sequence | Semi | [ | |
| Co-editing with plasmid-encoded selectable gene | “HDR-USR” (universal surrogate reporter) | Yes | [ |
| “ACBE-ARSR” Adenine and cytosine base editing antibiotic resistance screening reporter | Yes | [ | |
| “PEAR” Prime editor activity reporter | Yes | [ |